deepen yourunderstandingof tumor biology

Coronal Slices

Hypoxia occurs in tumors as a result of the poor ability of theirdisorganized vascular networks to deliver blood borne oxygen.
HypoxiSense detects the tumor cell surface expression of carbonic
anhydrase 9 (CA IX) protein, which increases in hypoxic regions
within many tumors, especially in cervical, colorectal, non-small
cell lung tumors. Pairing HypoxiSense with optical fluorescentimaging technology allows you to image and quantitate tumor
sub-regions undergoing hypoxia-related changes, non-invasivelyand in vivo.

Fluoresence Molecular Tomography Imaging

Coronal Slices

HypoxiSense™ FluorescentPre-clinical Imaging Agent

HypoxiSense is ideally suited for detecting hypoxia-inducedchanges in CA IX expression during:• Imaging in vivo mouse and rat tumors• Assessing therapeutic efficacy in drug
screening of tumor models• Fluorescence microscopy of disease tissues
For the first time, hypoxia can be measured non-invasively
in living mice and rats, as well as in ex vivo tissue samples.
It’s the perfect solution for the in vivo hypoxia researcher.

HypoxiSense
AngioSenseHeLa cervical cancer tumor cells were implanted in two subcutaneous sites on
the upper mammary fat pads of a nude mouse and allowed to grow to 600 mm3.
Simultaneous imaging with HypoxiSense 680 and AngioSense® 750 in living mice
reveals that both tumor hypoxia and vascular leak are occurring in both tumors.
As expected, coronal slices of tomographic imaging datasets further show discrete
regions of hypoxia throughout the tumors that do not co-localize with the sites ofvascular leak typically associated with angiogenesis.

HypoxiSense enables imaging of tumor hypoxia in both tomographic (subcutaneous and deep tissue tumors) and planar (subcutaneous tumors) opticalimaging systems. A representative mouse, bearing surface HeLa cervical cancer tumor xenografts, was injected intravenously with HypoxiSense and imaged
24h later using the FMT® 2500 Fluorescence Molecular Tomography imaging (left) and planar reflectance imaging (right).

HypoxiSense 680 clears from the bloodstream quickly, with a half-lifeof approximately 4 minutes, yet it accumulates within hypoxic regionsin tumor tissue with a half-life of 6h. Tumor hypoxia can be detected
as early as 3h post-HypoxiSense injection, with optimal signal to noise
measured at 12-24h once circulating agent has completely cleared.

HypoxiSense is optimized for use on PerkinElmer FMT
Quantitative Pre-clinical Imaging Systems, which enable deep
tissue interrogation of biomarkers and disease mechanisms.

NameDescription

Part Number

HypoxiSense 680

Fluorescent Pre-clinical Imaging Agent,
10 mouse doses

NEV11070

HypoxiSense 680 trial

Fluorescent Pre-clinical Imaging Agent,trial size

NEV11072

For more information, please visit: www.perkinelmer.com/hypoxiaPerkinElmer, Inc.
940 Winter Street
Waltham, MA 02451 USA
P: (800) 762-4000 or(+1) 203-925-4602
www.perkinelmer.com

For a complete listing of our global offices, visit www.perkinelmer.com/ContactUs
Copyright © 2011, PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc. All other trademarks are the property of their respective owners.
009849_01

Printed in USA

Sept. 2011